The findings of a study of reactogenic and clinical effects of a polycomponent vaccine derived from conditionally pathogenic microorganisms for immunotherapy of patients with chronic obstructive lung disease a represented. The vaccine was administered by a combined intranasal subcutaneous method (3 to 4 intranasal and 5 to 6 subcutaneous injections). 26 patients with chronic obstructive lung disease, mostly complicated by infectious allergic bronchial asthma were observed. 16 of those had severe, 8 — moderate, and 2 — mild disease. It was demonstrated that policomponent vaccine was characterized by low reactogenity. Antibody titers to vaccine components significantly increased as a result of immunotherapy. The clinical effectivity was defined by the change of disease gravity, duration of remission, possible reduction of initial medication; presence or absence of cough or sputum, auscultative findings, lung function parameters.

The immunotherapy of 26 patients had positive effect in 18 (69,2 %) of them, up to 2 months effect in 4, and no effect in 4 (15,4 %). The use of polycomponent vaccine increases the opportunities of therapeutic impact on those severe cases.